Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SNRS- Sunrise Technologies -- Ignore unavailable to you. Want to Upgrade?

To: Kevin Podsiadlik who wrote (3550)	12/18/1999 4:03:00 PM
From: Joe	Respond to of 4140

Kevin, I understand that this resubmission has a new PMA number. The indication has been changed from "correction of hyperopia" to "reduction of hyperopia". This is very significant change in language. I believe that what FDA may want in restrictive labeling is already built into the new labeling in this PMA. Further, the two Lehman analysts, both well known MD's in the financial community, are fully aware of the possible restrictive language the ODP may want. While at AAO, I had heard that they did more DD at Sunrise than any financial institution has done in the past. Joe

To: Kevin Podsiadlik who wrote (3550)	12/18/1999 8:01:00 PM
From: Stephen M. DeMoss	Read Replies (1) \| Respond to of 4140

You may be right but I tend to believe that the approval with new labeling in an area where we have no FDA approved treatment (non-evasive) at present, will support the stock at much higher levels than from here. In other words, any one short at this level will not be able to trade out with a profit, IF there is an approval. I know there is a risk of out right rejection. Having said that, I would NOT be short this stock at these levels. To me the risk reward is just not there (10 down and VISX type move up). Good luck to all. Steve D.